Get to Know Us
MSB-MET Ltd was established in 2007
using the biomedical measurements and research results accumulated over 25 years.
Our goal is to create high-end measurement and evaluation solutions for medical diagnostics and biological research that deliver exceptional quality and functionality in any environment. Until 2020, we worked in close consortium with EXPERIMETRIA Ltd.
2000s: development of biological research systems
- In vitro and in vivo pharmacological and physiological research measurement systems.
2010-2016: portfolio development
- Technological development and production of research measurement systems.
- Development and technologizing of human diagnostic measurement assessment systems.
2016-2023: further development of human diagnostics
- Further development of intelligent technology software.
- Development of effective integrated diagnostic systems for prevention and rehabilitation.
- Establishment of an independent quality management system (ISO, CE).
From 2023: Opening new diagnostic area
- Human diagnostic applications of myoelectric waves in visceral organs. In particular, the characterisation of diseases of the gastrointestinal tract (EGIG).
Target areas: reflux, stress / anxiety, gastroparesis, irritable bowel syndrome
, founded by György Grosz, operated as a corporate group with EXPERIMETRIA Ltd. 
from its establishment until 2020, with part of the products manufactured by MSB-MET Ltd. being sold by EXPERIMETRIA Ltd. to foreign markets. However, the consortium cooperation ended in 2020, and since then these companies have been operating entirely separately with no cooperation in development, production or sales from 2021.
The separation of the consortium in 2020 significantly changed the company’s market position – in a positive direction: the company’s operational structure was expanded to include a human diagnostics portfolio, which was required by global demands. The current staffing structure of our company is structured accordingly:
The human health segment covered by our company remains the non-invasive diagnostics of abnormalities (e.g. cardiac, sensory neuropathies) resulting from side effects of cardiovascular and metabolic diseases. Other market areas are agriculture, including animal husbandry, and sports, with a focus on health maintenance (prevention) and health restoration (rehabilitation).
The product development focus “diagnosis of pathological lesions in or from the visceral region based on the analysis of the myoelectric wave activity of the visceral region”, continues. The diagnosis of reflux, stress/anxiety and gastroparesis is currently in the clinical trial phase. This development concerns all three areas the company intends to cover. Market entry with this product line is expected in 2024-2026.
The development of the product line already marketed by our company has been progressing intensively since 2020. The main focus of the development here is on diagnostic and therapeutic support for prevention and rehabilitation. The need for these developments has been reinforced by the rehabilitation of pathological changes that have developed after recent epidemics, affecting almost the entire human body. For the measurement systems on the market, the main focus for further development is to provide a solution for health screening, as well as the automatic evaluation of the measurement data generated by the screening as well as the management of the evaluated data to develop further intelligent, self-learning systems. For the new systems, in addition to the features described above, the company has solved the integration of the measurement interfaces and has moved into the therapeutic interface of the rehabilitation area. This crossover has been achieved with the cardiovascular rehabilitation load system designed to support the therapeutic use of exercise. The results of these improvements were decisive in the revenues in 2021 – 2023, primarily in human diagnostic area.
